Is Cytokinetics Inc (CYTK) overvalued? · rev $18.5M
Cytokinetics Inc (CYTK) is a biotechnology company listed on US.
This page asks whether Cytokinetics Inc (CYTK) looks expensive on cached numbers — not a short thesis.
Latest reported CYTK revenue for 2024-12-31 was $18.5M. Net income was -$589.5M. Revenue was up 145.3% from 2023-12-31 to 2024-12-31. CYTK currently screens at market cap $4.05B.
CYTK currently screens at market cap $4.05B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CYTK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CYTK stock page for the full model, not this heading.
Not investment advice.